β-Hydroxyisovaleryl-Shikonin Exerts an Antitumor Effect on Pancreatic Cancer Through the PI3K/AKT Signaling Pathway

Pancreatic cancer (PC) is marked with a low survival rate and lack of recognized effective treatment strategy. We investigated the antitumor effect of beta-hydroxyisovaleryl-shikonin (beta-HIVS) on PC and the associated working mechanism. Cell toxicity was determined using Cell Counting Kit-8 (CCK-8) assay. Acridine Orange/Ethidium Bromide (AO/EB) double-fluorescent staining assay accompanied by flow cytometry was utilized to estimate cell apoptosis. Cell cycle, reactive oxygen species (ROS), and mitochondrial membrane potential were all evaluated using flow cytometry. Transwell and wound healing assays were performed to evaluate cell migration and invasion. Protein expression was analyzed by Western blots. A xenograft mouse model was employed to determine the antitumor effect of beta-HIVS in vivo. PC cell viability gradually decreased with increasing beta-HIVS while apoptosis was enhanced together with cell-cycle blockage in the G0-G1 phases. beta-HIVS induced mitochondrial dysfunction, ROS production, and DNA damage and inhibited the invasive and migratory ability of PC cells. We further confirmed the suppression of EMT and PI3K/AKT pathways as underlying mechanisms. The mouse model treated with the increasing dose of beta-HIVS displayed decreased tumor growth rate, along with increased apoptosis. Thus, beta-HIVS exerts antitumor effects on PC through inducing apoptosis, ROS production, decreasing mitochondrial membrane potential, and suppressing signal pathways, such as PI3K/AKT. In summary, beta-HIVS might be a promising strategy for PC treatment.

Automated summary

β-HIVS was found to inhibit the growth and invasion of pancreatic cancer through inducing apoptosis, increasing ROS production, decreasing mitochondrial membrane potential, and suppressing the PI3K/AKT pathways.